Complete Revascularization with pVAD vs IABP

Analysis Showcases Potential for More Complete Revascularizations with Impella® Heart Pumps Compared to IABP During High-Risk PCI

This page provides an overview about the York data analysis - a pooled Individual Patient Data (IPD) analysis of pVAD and IABP in high-risk PCI, presented by Vasileios Panoulas, MD, at EuroPCR 2023 (part one) and ESC 2023 (part two).

Part One: Complete Revascularization with pVAD vs IABP

In part one of the pooled data analysis led by the York Health Economics Consortium, Vasileios Panoulas, MD, and colleagues examined data from PROTECT II, PROTECT III and RESTORE EF to explore the hypothesis that using a percutaneous LVAD, such as Impella heart pumps, during high-risk percutaneous coronary intervention (HRPCI) helps achieve more complete revascularization (CR) compared to HRPCI supported with an intra-aortic balloon pump (IABP).

Part Two: Acute Coronary Syndromes and High-Risk PCI: State of the Art

In part two of the York data analysis, Dr. Panoulas and colleagues looked at data from PROTECT II and RESTORE EF to investigate the relationship between CR, New York Heart Association (NYHA) heart failure class and 90-day LVEF in patients undergoing HRPCI with either Impella or IABP. 


York Data Analysis About Complete Revascularization With pVAD vs IABP: Comparing Part One vs Part Two

Learn more about the differences and key points between part one and two of the York data set.

Complete Revascularization With pVAD vs IABP

At EuroPCR 2023, Vasileios Panoulas, MD, presented results of a third-party analysis comparing complete revascularization rates in high-risk PCI patients who received Impella support compared to IABP support.

Acute Coronary Syndromes and High-Risk PCI: State of the Art

Vasileios Panoulas, MD, and colleagues pooled individual patient data from the PROTECT II randomized controlled trial and the RESTORE EF study and found that baseline SYNTAX score, residual SYNTAX score and LVEF at baseline were significant predictors of NYHA class at 90 days after high-risk PCI.


A “Treasure Trove” of Complete Revascularization Data

Vasileios Panoulas, MD, discusses an individual patient data pooling from the PROTECT II RCT, PROTECT III and RESTORE EF trials released at EuroPCR 2023.

Learn More About Clinical Evidence Related to Impella


FDA Accepts and Closes Impella Post-Approval Studies for Major Indications

Chuck Simonton, MD, reviews that in October 2022 the FDA accepted and closed all Impella post-approval studies for high-risk PCI, cardiogenic shock, post-cardiotomy cardiogenic shock and right heart failure.


Influential Trials in High-Risk PCI

At TCT 2022, Jonathan Hill, MD, presents the influential high-risk PCI trials shaping the future of ischemic heart failure therapy.


RESTORE EF Case Study: Contemporary Practices for Impella-Supported Complete Revascularization

Jason Wollmuth, MD, describes best practice techniques for Impella-supported complete revascularization in a RESTORE EF case.

Subscribe to receive the latest clinical data and priority access to resources.